第二项后期ReNu研究错过了关键终点，器官发生遭遇挫折

2025-09-26 05:12

Organogenesis (NASDAQ:ORGO) said a second phase 3 trial of its cryopreserved amniotic suspension allograft ReNu missed its primary endpoint.
The first late-stage trial met the important mark.
ReNu, which is under investigation for treating knee osteoarthritis, did not achieve a statistically significant change in pain reduction.
Organogenesis said it would ask for a pre-BLA meeting with the US FDA by the end of October to examine a submission pathway, "including using the combined efficacy analysis from both Phase 3 studies to support a BLA approval," according to company COO Patrick Bilbo.

More on Organogenesis